Fulcrum Therapeutics, Inc.
NASDAQ:FULCBiotechnology
+$0.06 today
- Market cap
- $284.14M
- Beta
- 2.92
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.00
Volume 0.63M
Average 1.78M
FULC Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Fulcrum Therapeutics, Inc.NASDAQ: FULC
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$22.19M, compared with -$20.4M a year earlier. Trailing-twelve-month operating income was -$86.55M.
Context
- Operating income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 5 analysts of -$41.18M (+51.4%) for the fiscal year ending Dec 2026, a step up from the -287.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$22.19M+2.2% QoQ
- Last fiscal yearDec 2025
- -$84.77M-287.1% YoY
- LTMMar 2026
- -$86.55M-594.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -8.7% | — | — |
| 1 year | -287.1% | +51.4% | +338.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (84.77M) USD
- Year-over-year change
- -287.1%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (84.77M) | -287.1% |
| FY2024 | 2024-12-31 | (21.9M) | +80.2% |
| FY2023 | 2023-12-31 | (110.66M) | +1.7% |
| FY2022 | 2022-12-31 | (112.56M) | -38.9% |
| FY2021 | 2021-12-31 | (81.05M) | — |
Operating Income vs competitors
How FULC compares with its peers on the latest reported figures
- FULC's LTM Mar 2026 operating income of -$86.55M is the 5th highest of the 10 companies compared; the peer median is -$105.25M.
- Its year-over-year change of -594.3% is the lowest of 10, against a peer median of +2.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$24.23M | +86.3% | — | 34.8% | |
| LTM Mar 2026 | -$37.71M | -76.8% | — | 255.1% | |
| LTM Mar 2026 | -$66.25M | -16.1% | — | 1483.9% | |
| LTM Mar 2026 | -$75.17M | -21.6% | — | — | |
| LTM Mar 2026 | -$86.55M | -594.3% | — | — | |
| LTM Mar 2026 | -$105.25M | +36.3% | — | 1063.9% | |
| LTM Mar 2026 | -$110.76M | -23.4% | — | — | |
| LTM Mar 2026 | -$118.48M | +5.6% | — | 149.6% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$223.08M | +18.7% | — | — |
| LTM Mar 2026 | -$242.4M | +2.4% | — | 381.8% | |
| Peer median (excluding FULC) | -$105.25M | +2.4% | — | 318.4% | |
Competitors are the stored peer set for FULC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 19.16M | 6.34M | 2.81M | 80M | 0 |
| Cost of Revenue | 69.7M | 76.78M | 71.8M | 63.39M | 1.39M |
| Gross Profit | (50.54M) | (70.44M) | (69M) | 16.61M | (1.39M) |
| Gross Margin | -263.7% | -1110.7% | -2459.8% | 20.8% | — |
| Research & Development | 69.7M | 76.78M | 71.8M | 63.39M | 56.1M |
| Selling, General & Admin | 30.52M | 41.69M | 41.67M | 36.45M | 28.67M |
| Operating Expenses | 30.52M | 42.12M | 41.67M | 38.51M | 83.38M |
| Depreciation & Amortization | 2.52M | 2.41M | 2.17M | 1.59M | 1.39M |
| EBITDA | (78.33M) | (109.72M) | (95.16M) | (18.24M) | (73.49M) |
| EBITDA Margin | -408.8% | -1730.1% | -3392.6% | -22.8% | — |
| Operating Income | (81.05M) | (112.56M) | (110.66M) | (21.9M) | (84.77M) |
| Operating Margin | -423.0% | -1774.9% | -3945.2% | -27.4% | — |
| Interest Income | 207K | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 207K | 2.69M | 13.33M | 12.17M | 9.89M |
| Income Before Tax | (80.85M) | (109.87M) | (97.34M) | (9.73M) | (74.88M) |
| Pre-Tax Margin | -421.9% | -1732.4% | -3470.1% | -12.2% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (80.85M) | (109.87M) | (97.34M) | (9.73M) | (74.88M) |
| Net Margin | -421.9% | -1732.4% | -3470.1% | -12.2% | — |
| EPS (Basic) | (2.22) | (2.35) | (1.59) | (0.16) | (1.18) |
| EPS (Diluted) | (2.22) | (2.35) | (1.59) | (0.16) | (1.18) |
| Weighted Avg Shares | 35.36M | 44.99M | 61.31M | 61.98M | 63.36M |
| Weighted Avg Shares (Diluted) | 35.36M | 44.99M | 61.31M | 61.98M | 63.36M |
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
Intrinsic Alpha fair value
Locked
Current Price
$3.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.